ArticleBMC pulmonary medicine2025

Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study.

Haoting Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.